Tobacco Cessation Interventions

Tobacco cessation interventions are evidence-based practices designed to help individuals discontinue all forms of tobacco use, encompassing behavioral counseling, pharmacotherapy, and their combination, delivered across clinical and community settings.

Also Called: Smoking cessation interventions, tobacco treatment, tobacco dependence treatment, quit smoking programs, nicotine addiction treatment, tobacco use cessation.

Classification of Interventions

Tobacco cessation interventions are categorized by modality and intensity. The classification below reflects the three main evidence-based approaches, as supported by Cochrane systematic reviews ^{[1]A1a[2]A1a[3]A1a[4]A1a[5]A1a}.

These interventions are indicated for all tobacco users, including those who smoke cigarettes, use smokeless tobacco, or use other tobacco products. The choice of intervention depends on the individual's readiness to quit, preferences, and prior quit attempts, with combined therapy generally yielding the highest abstinence rates ^[2]A1a[4]A1a.

Clinical Significance

Tobacco use remains the leading preventable cause of death worldwide, and cessation interventions are among the most cost-effective preventive health services, significantly reducing the risk of tobacco-related morbidity and mortality. Systematic reviews demonstrate that even brief interventions by oral health professionals can increase abstinence rates by 71% (OR 1.71) ^[1]A1a, and behavioral support in dental settings yields a 1.86-fold increase in quit rates (RR 1.86, 95% CI 1.01 to 3.41) ^[2]A1a.

Understanding the neurobiological mechanisms underlying nicotine dependence provides the foundation for effective cessation interventions.

Pearl: Interventions are effective across diverse populations, including dental patients, young people, and those with substance use disorders, as supported by Cochrane reviews ^{[2]A1a[3]A1a[4]A1a}.

The mechanisms sustaining tobacco use are both neurobiological and psychosocial, with nicotine driving dependence through dopamine release in the mesolimbic pathway, while social and emotional contexts reinforce the behavior. In populations with substance use disorders (SUDs), the interplay is particularly strong: tobacco use intertwines with other substance use, heightening cravings and impacting efforts to remain abstinent ^[7]D5.

Psychosocial Functions of Tobacco

Qualitative evidence from people in SUD treatment reveals that tobacco serves multiple psychosocial functions that reinforce dependence. Smoking is a coping mechanism for stress, a tool for social connection, and a component of personal identity ^[7]D5[8]D5. For women with SUDs, these functions are amplified by intersecting marginalized identities, and smoking also serves as a response to stigmatization ^[8]D5. The behavior is not merely a habit but a deeply embedded psychosocial strategy that complicates cessation.

Barriers to Cessation

Physiological withdrawal symptoms, irritability, craving, anxiety, are a primary barrier ^[7]D5. Equally important are psychosocial barriers: using tobacco as a coping mechanism, reliance on smoking for social bonding, and limited cessation support within treatment programs and social environments ^[7]D5. Stigmatization around smoking further hinders quitting, as women report feeling judged ^[8]D5. Clinicians themselves face barriers, including organizational lack of support and tobacco-related misconceptions ^[8]D5.

Reinforcement Cycle

The qualitative data describe a reinforcement cycle: tobacco use heightens cravings for other substances, leading to increased use of both, which in turn strengthens tobacco dependence ^[7]D5. This cycle is particularly difficult to break without integrated interventions that address both the pharmacological addiction and the psychosocial functions.

Implications for Intervention

These mechanisms explain why effective tobacco cessation interventions must go beyond nicotine replacement. Integrating pharmacological interventions (e.g., nicotine replacement therapy) with psychosocial and behavioral counseling and social support can address the biological and psychosocial drivers simultaneously ^[7]D5[8]D5. Tailoring interventions to gendered experiences, such as providing non-stigmatizing counseling and alternative coping strategies for women, may improve outcomes ^[8]D5.

The mechanisms described here, the interplay of nicotine dependence, psychosocial reinforcement, and systemic barriers, directly underlie the epidemiology of tobacco use, the high prevalence among SUD populations, and the risk factors that will be discussed in the next section.

Pearl: Tobacco use is maintained by a self-reinforcing cycle of neurobiological addiction and psychosocial coping; effective cessation requires addressing both the withdrawal symptoms and the social and emotional functions of smoking.

The pathophysiologic mechanisms of nicotine addiction operate within populations that bear a disproportionate burden of tobacco use. Approximately 15% of young people smoke in developing countries (with wide variation) and 26% in the UK and USA ^[3]A1a. Among adults, global prevalence remains high: in India, 28.6% of adults use tobacco ^[17]B2a, and in pediatric emergency departments, 33.9% of parents accompanying children are smokers ^[15]C4.

Global Burden and Demographics

Tobacco use is concentrated among disadvantaged and vulnerable groups. People living with HIV are two to three times more likely to smoke than the general population ^[9]A1b. Persons with schizophrenia and related psychotic disorders smoke more and have twice the rate of mortality, with a 10- lower life expectancy ^[10]A1b. Among Indian cancer patients, 74% continue tobacco use after diagnosis, with 50% smoking and 34% using smokeless tobacco ^[17]B2a.

Risk Factors for Tobacco Use and Continued Use

Multiple risk factors predispose to tobacco initiation and impede cessation. The table below summarizes the main factors with their associated effect sizes.

Among young people, interventions that include motivational enhancement increase quit rates by 60% (RR 1.60, 95% CI 1.28-2.01) ^[12]A1a, this underscores the importance of targeting risk factors early. In military populations, behavioural and pharmacological interventions yield short-term (≤3 months) odds of cessation 2.03 (95% CI 1.49-2.77) and long-term (≥6 months) OR 1.53 (95% CI 1.12-2.09) ^[16]A1a.

Temporal Trends and Special Populations

Tobacco prevalence is declining in some high-income countries but remains high in low- and middle-income settings. The prevalence of continued use after cancer diagnosis has not significantly decreased, highlighting the need for integrated cessation services in oncology ^[17]B2a. People living with HIV in sub-Saharan Africa have particularly high tobacco use rates, with studies ongoing to test phone-based interventions ^[13]D5.

Pearl: When assessing a patient's risk for tobacco-related harm, ask about comorbid HIV, mental illness, or TB, these conditions more than double the likelihood of ongoing tobacco use and warrant targeted cessation interventions.

Controversies and Guideline Disagreement

Beyond the robust epidemiologic associations with psychosis, substance use, and ethnic disparities, the clinical presentation of tobacco use disorder encompasses a spectrum of dependence severity, motivation to quit, and comorbidity burden that directly shapes intervention strategy. The patient who smokes is not a single entity; heterogeneity in nicotine metabolism, psychiatric comorbidity, and cultural context creates distinct clinical phenotypes that clinicians must recognize to tailor cessation counseling.

Patterns of Tobacco Use

Use patterns vary by population. Among US adults with psychosis, past-month any tobacco use is 41.3% vs 27.7% in those without psychosis (adjusted risk ratio 1.49) ^[18]C4. Dual cigarette and e-cigarette use is 13.5% vs 10.1%, and polycombustible plus noncombustible tobacco use reaches 22.1% vs 12.4% ^[18]C4. In contrast, Hispanic smokers along the US/Mexico border are typically light smokers with low nicotine dependence, a high number of past quit attempts, and limited use of cessation aids ^[21]C4. Among American Indian and Alaska Native (AIAN) communities, 92% of survey respondents were aware of tobacco risks and 76% considered it a community problem, yet only 29% had any knowledge of pharmacogenomics as a tool for cessation ^[22]C4.

Dependence Severity

Nicotine dependence is more severe in patients with psychosis. The mean nicotine dependence score (PATH Study) was 54.6 vs 49.5 ^[18]C4. This elevated dependence drives higher rates of poly-use and makes unaided quitting less likely. In a cohort from an Indian tobacco cessation clinic, 23.14% of participants had quit at 6 months and 74.38% had reduced use, but the majority received only behavioral counseling (65.35%) rather than combination therapy ^[24]C4.

Motivational Stage and Prior Quit Attempts

Many patients present with a history of multiple quit attempts but without sustained success. Only one in three current smokers with schizophrenia reported that their primary care provider or psychiatrist had assisted them in obtaining medications for tobacco cessation ^[20]C4. This missed opportunity reflects a gap between the prevalence of quit attempts and the delivery of evidence-based pharmacotherapy. Brief interventions, as short as 1 minute, increase the quit attempt rate threefold, but are inconsistently delivered in settings such as emergency rooms ^[19]C4.

Special Populations

Red Flags

Certain clinical presentations should prompt intensified intervention. Patients with psychotic disorders who smoke heavily underestimate their lung cancer risk: among older adults with schizophrenia who met lung screening criteria, >50% believed they had low risk ^[20]C4. This misperception, combined with infrequent delivery of cessation medications, represents a critical missed opportunity. Similarly, in AIAN communities, concerns about genetic material handling and result dissemination require transparent communication before pharmacogenomics-based approaches can be trusted ^[22]C4.

Pearl: When a patient with psychosis or a heavy smoking history expresses low concern about lung cancer risk, probe for prior cessation attempts and explicitly offer pharmacotherapy, the gap between perceived risk and actual risk is a direct call to action, not a reassurance.

Atypical Presentations

Not all tobacco use presents as daily cigarette smoking. Smokeless tobacco use, common in rural Appalachia, is often underrecognized by clinicians in non-dental settings. Emergency room nurses trained in a brief (1-minute) Ask-Advise-Refer strategy increased their motivation and self-efficacy to address smokeless tobacco, but the intervention is rarely delivered ^[19]C4. Clinicians should routinely ask about all forms of tobacco, including chewing tobacco, snus, and dissolvables, particularly in regions with high smokeless prevalence.

Identify tobacco exposure

Establish whether the patient currently uses tobacco, the product used (cigarettes, smokeless tobacco, or other tobacco products), frequency of use, duration, and time since last use. Assessment should include patients with cancer, HIV, tuberculosis (TB), chronic obstructive pulmonary disease (COPD), diabetes, serious mental illness, psychosis, pregnancy, substance-use disorders, and transplant history because tobacco exposure and cessation needs may be clinically important in each setting ^{[17]B2a[18]C4[31]B2c[38]C4[69]B3b[73]C4[79][82]}. In India, a systematic review identified 20 observational studies of continued smoking, smokeless-tobacco use, or both after cancer diagnosis; the review contextualized this problem against an adult tobacco-use prevalence of 28.6% ^[17]B2a.

For patients with cancer, document tobacco use at diagnosis and at each subsequent clinical encounter. Continued use after diagnosis is sufficiently common to warrant active reassessment rather than assuming cessation ^[17]B2a. Cessation around diagnosis is clinically consequential: an umbrella review reported mortality reductions of 15–29% in lung cancer, 20% in head and neck cancer, and 24% in colorectal cancer among patients who quit after diagnosis, with suggestive benefits in breast, bladder, and gastrointestinal cancers ^[28]D5.

Characterize nicotine dependence and cessation history

Record cigarettes or tobacco units per day, time to first use, craving, withdrawal symptoms, use in restricted settings, unsuccessful quit attempts, longest abstinence interval, prior counseling, and prior pharmacotherapy. Assess motivation and the intended quit horizon; in a COPD registry, intention to quit within the next 30 days was the primary behavioral outcome examined in relation to respiratory symptoms and disease-severity markers ^[38]C4. Document whether the patient is preparing to quit, has recently quit, or is maintaining abstinence. Long-term follow-up is relevant because a prospective five-year study reported that 29.6% of the 267 participants followed remained abstinent at five years after cessation care ^[81].

Evaluate all tobacco products and concurrent substance use. Smoking prevalence in people receiving treatment for alcohol or other drug dependence is reported to be two to four times that of the general population, and a Cochrane review evaluated whether tobacco-cessation treatment can be delivered concurrently without compromising recovery from other addictions ^[4]A1a. Patients should therefore not be excluded from tobacco assessment because they are in substance-use treatment or recovery ^[4]A1a.

Assess psychiatric, reproductive, and medical comorbidity

Screen for depression, anxiety, psychosis, serious mental illness, and other factors that may affect readiness, adherence, withdrawal, or relapse. A nationally representative study compared tobacco-product use, nicotine-dependence severity, and cessation methods in community-dwelling adults with and without psychosis ^[18]C4. In an integrated-care cohort, use of cessation pharmacotherapy was examined among smokers with type 2 diabetes with versus without serious mental illness ^[69]B3b. These populations require coordinated assessment rather than a presumption that psychiatric illness precludes cessation treatment ^{[4]A1a[18]C4[69]B3b}.

For patients who are pregnant or planning pregnancy, document prepregnancy smoking, current prenatal smoking, depression or anxiety, and cessation by late pregnancy. A population-based analysis of 34,633 women with live births examined these measures according to reported depression or anxiety ^[73]C4. Postpartum assessment should also consider depressive symptoms because a 2015–2020 analysis of 218,128 PRAMS participants evaluated the association between tobacco smoking and postpartum-depression symptom severity ^[36]C4.

Assess tobacco-related disease burden and treatment context, including respiratory symptoms and pulmonary function when COPD is suspected, diabetes control, TB status, cancer diagnosis, and transplant status. In TB care, an integrated intervention linked cessation support with directly observed therapy, and a related multicenter study evaluated effects on health-related quality of life among 120 Malaysian patients who smoked at TB diagnosis ^[11]B2b[80]. After lung transplantation, tobacco resumption was reported in 4% of one retrospective cohort; COPD, shorter pretransplant cessation duration, and the pack-year–cessation index were associated with post-transplant use ^[79].

Verify abstinence when clinically or methodologically important

Self-reported abstinence may be supplemented by biochemical testing when confirmation affects clinical decision-making, research validity, or transplant assessment. In a randomized trial among people with HIV in South Africa, abstinence at 6 months was self-reported and biochemically validated using exhaled-breath carbon monoxide and urine cotinine ^[26]A1b. The trial randomized 280 participants with HIV who smoked to intensive behavioral counseling alone or counseling plus combination nicotine replacement therapy consisting of nicotine patches and gum ^[26]A1b.

Document access, engagement, and follow-up needs

Record barriers to cessation care, including geographic dispersion, mental-health symptoms, limited resources, hospitalization transitions, and digital-access or engagement problems. A randomized-trial protocol in young cancer survivors aged 18–40 years compared a smartphone application with in-person mindfulness-based cessation intervention, specifically addressing geographic reach and depression-related relapse risk ^[78]. Among hospitalized smokers, pooled randomized-trial data evaluated interactive voice-response calls after discharge, including intervention use, satisfaction, and the relationship between call dose and cessation ^[25]B2b. Digital intervention records may help identify early dropout; a 2024 replication study examined whether first-week log-in and engagement data predict withdrawal from multimodal digital cessation programs ^[30]B3b. Telephone callback counseling has also been evaluated using cost-effectiveness and productivity modeling ^[32]B2c.

The workup should end with a documented diagnosis of current tobacco use or abstinence, an assessment of dependence and readiness, relevant comorbidities and contraindication considerations, prior treatment response, objective-verification needs, and a follow-up plan. Dental settings and TB services are additional opportunities to identify tobacco use and connect cessation care with routine treatment ^{[11]B2b[29]A1a[80]}.

Scope of assessment

Tobacco-use severity should be characterized across several domains rather than by cigarettes per day alone: current product use, nicotine dependence, tobacco-use pattern, psychiatric or medical comorbidity, functional vulnerability, readiness to quit, and barriers to treatment. The available evidence is heterogeneous, consisting of cross-sectional studies, observational cohorts, systematic reviews, and one trial protocol; therefore, associations should not be interpreted as proof of causation or as universally validated staging thresholds. ^{[18]C4[35]C4[36]C4[37]C4[33]A1a[5]A1a[34]D5}

Dependence and tobacco-use stage

Document whether the patient is a non-user, single-product user, or poly-tobacco user. This distinction is clinically relevant because national veteran data explicitly classified tobacco use into these three categories and evaluated their relationship with functional difficulties. ^[37]C4 Record the specific products used, frequency, duration, quantity, concurrent products, and previous quit attempts. In adults with psychotic disorders, assessment should specifically include the type of tobacco product, nicotine-dependence severity, and cessation methods previously attempted; these were central outcomes in a nationally representative US study of community-dwelling adults aged ≥18 years. ^[18]C4

Nicotine dependence can be staged using a validated dependence instrument, with the Fagerström Test for Nicotine Dependence used in a study of caregivers of patients with severe mental disorders. ^[35]C4 The supplied evidence does not provide a universal numerical Fagerström cut-off for treatment intensity. One longitudinal cessation study instead allocated routine minimum intervention to smokers with mild addiction and to those not in the preparation stage, while nicotine-replacement therapy was used for patients with moderate-to-high dependence and/or high tobacco consumption. ^[81] Thus, dependence severity and readiness should be recorded separately: a patient may have substantial dependence but low immediate readiness, or lower dependence but high readiness for a quit attempt. ^[81]

Clinical severity and risk modifiers

Assess tobacco-related disease burden and symptoms. In smokers with COPD or fixed airflow obstruction identified by pulmonary function testing, respiratory and bronchitic symptoms, together with other markers of COPD severity, were evaluated as predictors of intention to quit within the next 30 days. ^[38]C4 Symptoms and physiologic impairment should therefore be incorporated into risk stratification, while recognizing that the cited study was cross-sectional and examined intention rather than confirmed abstinence. ^[38]C4

Pulmonary tuberculosis is a high-risk context: active smoking is associated with approximately 2- to 2.5-fold higher risk of tuberculosis infection and has been associated observationally with recurrent tuberculosis, mortality, loss to follow-up, greater disease severity, drug resistance, and slower smear conversion. ^[33]A1a The same review notes that many smoking-related immunologic abnormalities are reversible within approximately 6 weeks of cessation, supporting urgent intervention during tuberculosis treatment. ^[33]A1a

Psychiatric illness and psychosocial vulnerability warrant explicit risk designation. Adults with psychotic disorders have high premature mortality and high smoking prevalence, making tobacco cessation a priority in this population. ^[18]C4 In rural families of patients with severe mental disorders, caregiver tobacco dependence was measured alongside patient psychiatric symptom severity and reported verbal or physical caregiver abuse; the study specifically tested whether tobacco dependence moderated the association between symptom severity and abuse. ^[35]C4 These findings support assessment of household safety, caregiver dependence, psychiatric symptoms, and treatment access, but the cross-sectional design does not establish directionality. ^[35]C4

Postpartum mental-health risk should also be considered. A large cross-sectional analysis of 218,128 mothers in the Pregnancy Risk Assessment and Monitoring System evaluated recent tobacco use in relation to postpartum-depression symptom levels using multinomial models and sensitivity analyses for unmeasured confounding. ^[36]C4 Tobacco use should therefore prompt assessment of postpartum depressive symptoms and their severity, although the supplied abstract does not provide effect estimates or establish causality. ^[36]C4

Functional and social vulnerability

Disability-related functional difficulty may identify patients requiring adapted cessation support. Among US veterans, the cited national survey categorized functional difficulty as none, some, or significant and examined associations with non-use, single-product use, and poly-tobacco use after sociodemographic adjustment. ^[37]C4 Veterans with functional difficulties should receive assessment of mobility, cognition, communication, transportation, housing, and ability to follow a treatment plan; the supplied abstract reports higher odds of cigarette use among veterans with some functional difficulties but does not provide complete estimates for all use categories. ^[37]C4

Homelessness is a major access and risk-stratification factor. A Cochrane review addressed interventions intended both to improve access to cessation treatment and to increase tobacco abstinence among adults experiencing homelessness, a population described as having high tobacco-use rates, substantial cessation barriers, and considerable tobacco-related morbidity and mortality. ^[5]A1a Housing instability, competing health needs, access to medication, and continuity of follow-up should therefore be recorded when assigning intervention priority. ^[5]A1a

Readiness, prognosis, and treatment priority

Readiness to quit is an independent staging dimension. In the five-year longitudinal study, action-stage status and nicotine-dependence-informed treatment allocation were examined as predictors of sustained abstinence; among 267 participants followed for five years, 29.6% remained abstinent at that point. ^[81] This supports documenting current stage of change and arranging repeated reassessment rather than excluding patients who are not yet prepared to quit. ^[81]

Emergency-department presentation is an opportunity for proactive risk identification, but the cited INITIATE study is a protocol rather than an outcome report. It was designed to test a simple, multicomponent “quit card” intervention against usual care in a multicenter randomized trial because prior emergency-department interventions had limited success related to time, motivation, and incentives. ^[34]D5 Accordingly, emergency-department patients should be screened and offered linkage to continuing treatment, while effectiveness conclusions should await trial results. ^[34]D5

Practical risk categories

A high-priority profile includes moderate-to-high dependence or high consumption, current respiratory disease or tuberculosis, psychotic or severe mental disorder, postpartum depressive symptoms, homelessness, substantial functional difficulty, poly-tobacco use, or repeated unsuccessful quit attempts. ^{[81][33]A1a[18]C4[35]C4[36]C4[5]A1a[37]C4} A lower apparent risk profile should not be equated with low benefit from cessation: all current tobacco users should receive assessment, brief intervention, and follow-up appropriate to their readiness and clinical context. ^{[5]A1a[33]A1a[34]D5}

Clinical priorities

Acute-care encounters are opportunities to identify tobacco use, deliver an immediate cessation message, and connect the patient with continuing support. Emergency-department (ED) patients have higher tobacco-use rates than the general population, and professional organizations have recommended cessation interventions in emergency settings. ^[42]D5 The approach should be brief, standardized, and feasible within the time constraints of acute care. ^[34]D5

Use the 5 A’s framework: Ask about current tobacco use, Advise cessation, Assess readiness to quit, Assist with a quit attempt, and Arrange follow-up. ^[83] When time is extremely limited, a concise Ask–Advise–Refer approach is appropriate; a rural emergency-room training program specifically taught the 2 A’s plus 1 R model—Ask, Advise, and Refer—for smokeless-tobacco users. ^[19]C4

Immediate intervention

Ask every patient, where clinically appropriate, about cigarette, smokeless-tobacco, and other tobacco use, then provide clear, personalized advice to stop. ^[83] A 30-second intervention was evaluated among smokers seeking emergency assistance from a community organization, demonstrating that cessation messaging can be incorporated into a brief service encounter rather than being restricted to conventional medical visits. ^[40]A1b A separate rural emergency-room program used a 1-minute-or-less brief-intervention model for smokeless-tobacco users and trained nurses to deliver it. ^[19]C4

Assess willingness to make a quit attempt and tailor the next step to the patient’s readiness. ^[83] For patients willing to quit, provide practical assistance and an active referral rather than only general advice. ^[15]C4 In a pediatric ED intervention, parental smokers received the first two A’s—Ask and Advise—combined with a fax referral to the state tobacco quitline. ^[15]C4 This model is relevant when the smoker is an accompanying parent or caregiver rather than the patient receiving treatment. ^[15]C4

For patients who are not ready to quit, use the encounter to reinforce the benefits of cessation, offer referral information, and preserve an opportunity for later engagement. ^[83] Community-based delivery may be particularly important for people living in poverty, who have a higher prevalence of smoking and disproportionate tobacco-related harm and may be missed by conventional cessation-delivery strategies. ^[40]A1b

Referral and follow-up

Arrange continuity after discharge or the acute encounter by referring patients to a tobacco quitline or another cessation service and documenting the referral. ^[15]C4 The ED “quit card” model was developed as a proactive, multicomponent intervention intended to address limited time, variable motivation, and the difficulty of delivering complex cessation treatment in a fast-paced ED. ^[34]D5 The INITIATE study protocol planned a multicenter randomized trial comparing this quit-card intervention with usual care among tobacco users presenting to the ED. ^[34]D5

Hospitalization can also be used to initiate treatment and follow-up. The Ottawa Model for Smoking Cessation was evaluated among current smokers recruited during admission to 14 hospitals and compared with usual care over 2 years; the intervention group experienced significantly lower rates of all-cause readmission. ^[44]B2b Inpatient psychiatry is an important setting for cessation support because smoking prevalence is disproportionately high among people with severe mental illness, while interest in quitting is reported to be comparable with that of the general population. ^[41]A1a

Implementation in acute-care teams

Acute-care nurses and clinicians may not apply all elements of the 5 A’s consistently. A multicenter survey of ED providers examined reported adherence to guideline-based cessation practices and preferences for intervention style; providers reported their strongest adherence for asking about tobacco use. ^[39]C4 Another survey examined relationships among use of the 5 A’s, individual and organizational attributes of excellence, and clinicians’ intention to make cessation intervention part of routine acute and critical-care practice. ^[83] Training can improve delivery: a 1-hour asynchronous program for rural ED nurses addressing smokeless tobacco and the Ask–Advise–Refer strategy produced significant positive pre- to post-training changes. ^[19]C4

Interventions should be acceptable to both patients and staff. The pediatric ED study specifically assessed acceptability among parental smokers and physicians or nurse practitioners caring for their children. ^[15]C4 Community-based testing also assessed satisfaction with the host organization and interest in cessation-related support after a very brief intervention. ^[40]A1b

Contextual triggers and risk reduction

Ask about situations that may undermine a quit attempt, including alcohol use. Analysis of tobacco- and alcohol-related online discussions identified co-use, increased susceptibility to tobacco use during drinking, and alcohol’s role in failed quit attempts as relevant themes among youth and young adults. ^[43]D5 This supports incorporating brief counseling about alcohol-associated triggers when they are disclosed, while maintaining the immediate focus on referral and cessation support. ^[43]D5

Evidence limitations

Evidence specific to ED cessation has been synthesized in a systematic review covering adult and pediatric ED interventions identified through February 2014. ^[42]D5 However, the cited literature includes pilot studies, surveys, implementation evaluations, and trial protocols as well as comparative effectiveness research; therefore, the strength and generalizability of evidence differ across settings and intervention components. ^{[34]D5[39]C4[40]A1b[42]D5[44]B2b} The cited sources do not establish a single universally superior acute-care intervention, so local pathways should prioritize reliable identification, brief advice, active referral, and arranged follow-up. ^{[15]C4[34]D5[42]D5[83]}

Core management strategy

Tobacco dependence should be managed as a chronic, relapsing condition with repeated assessment, a documented quit plan, behavioral support, pharmacotherapy when appropriate, and continuing follow-up rather than a single brief cessation encounter ^{[45]A1c[46]A1a}. The USPSTF evidence review supports behavioral interventions and FDA-approved pharmacotherapy for adults who use tobacco, while emphasizing individualized treatment and assessment of benefits, harms, preferences, comorbidities, pregnancy status, and tobacco product used ^{[45]A1c[46]A1a}. Combined behavioral and pharmacological treatment is an important long-term strategy because interventions addressing both nicotine dependence and behavioral triggers are used across clinical and high-risk populations ^{[16]A1a[26]A1b[49]A1a[50]A1b}.

Offer structured behavioral support, including advice to set a quit date, identify triggers, develop coping strategies, obtain social support, and plan for lapses and relapse ^{[45]A1c[46]A1a}. Support may be delivered individually, in groups, by telephone, through primary care, or digitally; the evidence base includes clinical, mobile-health, chatbot, text-messaging, and internet-based approaches ^{[45]A1c[46]A1a[53]A1b[87]}. A pragmatic multicenter randomized trial evaluated a smartphone chatbot as an adjunct or alternative to usual primary-care cessation practice, supporting digital tools as scalable complements to clinician-delivered care ^[53]A1b. An umbrella review specifically assessed long-term effectiveness, defined as at least 6 months, and adherence of standalone text-message, smartphone-app, internet, and artificial-intelligence modalities ^[87].

Pharmacotherapy and combination treatment

For nonpregnant adults, offer an evidence-based cessation medication unless contraindicated or declined, and combine it with behavioral counseling when feasible ^{[45]A1c[46]A1a}. Combination nicotine-replacement therapy, such as a nicotine patch plus short-acting nicotine gum, has been tested with intensive counseling in people living with HIV in a low-resource South African setting; the randomized trial enrolled 280 participants and used biochemical validation with exhaled carbon monoxide and urine cotinine at 6 months ^[26]A1b. This supports adapting established cessation treatment to populations receiving HIV care, while recognizing that medication access, adherence, interactions, and local resources require individualized planning ^[26]A1b[85].

Evidence also supports integrating cessation into oncology care. A systematic review with meta-analysis examined randomized trials among patients and caregivers affected by non-respiratory cancers, including breast, prostate, colorectal, cervical, and bladder cancer, because persistent tobacco use after diagnosis remains clinically important ^[49]A1a. Continued tobacco use after cancer diagnosis is also documented in an Indian systematic review and meta-analysis of 20 observational studies, underscoring the need to continue cessation treatment throughout cancer care rather than treating diagnosis as an endpoint ^[17]B2a.

Tailoring for complex and underserved populations

Military personnel and veterans may benefit from both behavioral and pharmacological interventions; a 2025 meta-analysis included 5 randomized trials involving 2,619 participants and evaluated short-term and longer-term abstinence outcomes ^[16]A1a. Veterans experiencing homelessness were studied in a randomized comparative-effectiveness trial of mobile contingency management, telehealth counseling, optional pharmacotherapy, and standard Veterans Affairs care; 127 participants were followed with biochemically verified outcomes and a longer-term financial incentive assigned at 3 months ^[84]. Contingency management may also be considered for smokers with depressive symptoms, although the systematic review identified only 6 eligible studies, requiring careful interpretation of the evidence ^[88].

Adults with serious mental illness should receive integrated behavioral and pharmacological cessation care rather than being excluded from treatment ^[50]A1b. In a pilot randomized trial, a 12-week program combined game-based group physical activity, counseling, and pharmacotherapy; among 48 participants, cigarette consumption declined by an average of 2.9 cigarettes per week over time, although the pilot design limits certainty about definitive abstinence effects ^[50]A1b.

People living with HIV should be offered cessation treatment within routine HIV services. A three-arm pragmatic randomized trial in 13 outpatient HIV clinics in Hanoi compared behavioral intervention strategies with and without pharmacotherapy and was designed to assess long-term effectiveness ^[9]A1b. An accompanying implementation case study described theory-driven adaptation and implementation strategies for introducing tobacco-dependence treatment into HIV clinics where cessation services were previously unavailable ^[85].

Digital delivery, incentives, and health-system implementation

Digital interventions can extend access but should complement, not replace, clinical assessment when medication, psychiatric comorbidity, pregnancy, or relapse risk requires clinician input ^[53]A1b[87]. A randomized trial among Chinese health-care providers tested an 8-week WeChat-based cessation-training program with follow-up to 34 weeks, aiming to increase use of evidence-based cessation practices ^[51]A1b. Digital outreach can also improve the completeness of smoking histories in electronic medical records, which is relevant to identifying patients for cessation and lung-cancer-screening pathways ^[86].

Contingency management and financial incentives may be useful adjuncts for selected populations, particularly when objective abstinence monitoring is feasible ^[84][88]. However, implementation should account for equity, sustainability, privacy, feasibility of biochemical verification, and the risk that incentives may not be available after the intervention ends ^[84][88]. South Asian clinical-setting evidence includes 37 studies, of which 22 were randomized, evaluating behavioral, pharmacological, and multicomponent interventions; the review highlights the importance of adapting cessation delivery to settings where access remains limited ^[59]A1a. Dental services can also deliver smokeless-tobacco cessation support, and a Pakistani process evaluation examined dentist-delivered behavioral intervention in dental hospitals ^[58]C4.

Follow-up and quality assurance

At every follow-up, reassess tobacco use, withdrawal, medication adherence, adverse effects, mood, triggers, exposure to other tobacco products, and readiness to continue abstinence ^{[45]A1c[46]A1a}. Relapse should prompt renewed treatment rather than discharge from care ^{[45]A1c[46]A1a}. Trial interpretation should consider selection, performance, detection, attrition, and selective-reporting bias using tobacco-cessation-specific risk-of-bias guidance ^[52]D5. Evidence among university students includes 18 studies, with 11 contributing to meta-analysis, but heterogeneity and study-quality limitations require cautious generalization to other populations ^[89].

Pregnant persons require particularly careful individualized counseling because smoking is associated with adverse pregnancy and offspring outcomes; behavioral interventions are the principal evidence-based approach, with medication decisions requiring discussion of potential benefits and harms ^{[45]A1c[46]A1a}. E-cigarettes should not automatically be treated as definitive cessation therapy because the USPSTF evidence review evaluated their effectiveness and safety separately and found that evidence informing routine recommendations remained limited ^{[45]A1c[46]A1a}.

From brief advice to guideline-based treatment

Early tobacco-cessation treatment was organized around systematic identification of tobacco use, brief advice, and referral to more intensive support. The 2009 USPSTF reaffirmation retained a Grade A recommendation to ask all adults about tobacco use and provide cessation interventions to those who use tobacco; it also recommended asking all pregnant women about tobacco use and providing augmented, pregnancy-tailored counseling to those who smoke. ^[60]A1c This recommendation was based on the USPSTF’s review of the 2008 U.S. Public Health Service clinical practice guideline and reaffirmed that the net benefits of cessation interventions in adults and pregnant women were well established. ^[60]A1c

The 2021 USPSTF statement broadened the population framework to include adults who use tobacco, including pregnant persons, and emphasized tobacco use as a leading preventable cause of disease, disability, and death. ^[45]A1c The statement reported that approximately 50.6 million U.S. adults (20.8%) used tobacco in 2019, including 14.0% who currently smoked cigarettes and 4.5% who used electronic cigarettes. ^[45]A1c It also highlighted pregnancy-specific risks, including miscarriage, congenital anomalies, sudden infant death syndrome, and impaired childhood lung function. ^[45]A1c

Expansion of delivery settings and providers

Treatment progressively moved beyond conventional medical consultations. A 2008 pediatric emergency-department intervention applied the first two “A’s”—Ask and Advise—combined with fax referral to a state quitline for smoking parents accompanying children; the study evaluated acceptability among both parents and clinicians. ^[15]C4 Pharmacists also became cessation providers: a U.S. randomized trial compared a pharmacist-delivered face-to-face group program with brief telephone standard care and used biochemical confirmation of abstinence. ^[92]

Community-based delivery was developed to reach populations poorly served by routine healthcare. In a 2007 pilot among smokers seeking emergency assistance from a Salvation Army agency, participants were randomized to a 30-second smoking intervention or no intervention, with satisfaction and interest in cessation assessed during the visit. ^[40]A1b In India, the BABEX cluster-randomized trial assigned 32 low-income administrative blocks and evaluated a brief tobacco-cessation intervention delivered by health workers to 1,213 adult tobacco users. ^[71]A1b A separate four-arm cluster-randomized study among 646 call-centre employees in India evaluated multiple cessation strategies over 18 months, reflecting the adaptation of treatment to occupational settings. ^[93]

Interventions also became more tailored. Qualitative follow-up of participants exposed to lay health influencers found that 86% reported modifying their intervention behavior according to individual smoker characteristics, their relationship with the smoker, or the setting. ^[64]C4 For smokers with low socioeconomic status, proactive outreach using electronic health-record smoking documentation was tested as a strategy to address socioeconomic disparities and offer tobacco treatment directly to disadvantaged smokers. ^[47]A1b

Continuity of care and post-discharge treatment

Hospitalization emerged as a high-yield opportunity to initiate cessation treatment, but subsequent research emphasized that counseling begun in hospital must continue after discharge. The Helping Hand 2 randomized trial enrolled 1,357 daily smokers across three hospitals and compared sustained post-discharge care with standard care after in-hospital counseling; sustained care began at discharge and incorporated referral to a nationally available telephone quitline. ^[63]A1b Interactive voice-response telephone calls were subsequently evaluated as an automated method for maintaining treatment after discharge. A pooled analysis included 878 hospitalized smokers who had received in-hospital counseling and planned to stop smoking after discharge, examining intervention exposure, satisfaction, and the relationship between intervention dose and cessation. ^[25]B2b

Adaptation for mental illness and other high-risk groups

Treatment evolution increasingly recognized that standard interventions may require adaptation for people with serious mental illness. A community mental-health study compared a telephone quitline intervention involving counseling and nicotine replacement therapy with community-based group counseling; at six months, both approaches reduced tobacco use, while participants receiving both services were more likely to achieve a 50% reduction in tobacco use. ^[90] A randomized study in people with schizophrenia and related psychotic disorders assigned 170 participants to a personalized cessation package or brief advice to stop tobacco, with outcomes assessed at baseline and at 1, 3, and 6 months. ^[10]A1b More recently, a pilot randomized trial combined counseling and pharmacotherapy with game-based group physical activity or sedentary games; the intervention consisted of 50-minute sessions three times weekly for 12 weeks, and the sample initially smoked an average of 56.3 cigarettes per week. ^[50]A1b

People living with HIV have also become a specific target population. In South Africa, a randomized trial among 280 people with HIV compared intensive behavioral counseling alone with counseling plus combination nicotine-replacement therapy consisting of nicotine patches augmented by nicotine gum; abstinence at six months was biochemically validated using exhaled carbon monoxide and urine cotinine. ^[26]A1b A pragmatic three-arm randomized trial in 13 outpatient HIV clinics in Hanoi evaluated behavioral cessation interventions with and without pharmacotherapy among adults living with HIV, a population reported to smoke at two to three times the rate of the general population. ^[9]A1b

Digital, mobile, and system-level interventions

The most recent phase has focused on scalability, automation, and implementation. A multicenter randomized trial in Spanish primary care compared the smartphone conversational chatbot Dejal@bot with usual clinical practice as a potentially scalable complement to treatment. ^[53]A1b A systematic review and meta-analysis of randomized trials published since 2005 assessed conversational artificial-intelligence interventions, with sustained abstinence for at least 6 months as the primary outcome. ^[91]

Digital tools have also been used to improve clinician implementation. In China, the randomized “WeChat WeQuit” program delivered smoking-cessation training messages to 942 healthcare providers for 8 weeks, compared with 945 controls, and followed participants for 34 weeks to assess use of standard cessation practices. ^[51]A1b Patient-generated digital data have been tested to improve identification of tobacco use: a pragmatic trial compared electronic-portal questionnaires with SMS text-message surveys among adults aged 50–80 years with a tobacco-use history, addressing incomplete smoking histories that can limit lung-cancer screening and cessation outreach. ^[86]

Overall, treatment has evolved from brief, clinician-initiated advice toward multimodal, continuously supported, and population-tailored care that combines counseling, pharmacotherapy, quitlines, community health workers, proactive electronic outreach, and conversational digital systems. ^{[45]A1c[60]A1c[47]A1b[63]A1b[91]}

Scope and clinical problem

Tobacco use should be treated as a routinely identifiable, modifiable clinical risk rather than a problem requiring diagnostic certainty before intervention. Emergency-department (ED) patients have higher tobacco-use rates than the general population, making acute-care encounters an important opportunity to initiate cessation support ^[42]D5. The Society for Academic Emergency Medicine and the American College of Emergency Physicians have recommended ED-based cessation interventions, yet emergency clinicians have reported uncertainty about their benefits and practical implementation ^[42]D5.

The supplied evidence does not identify a validated point-of-care tobacco-cessation score, numeric readiness cutoff, or disease-specific referral threshold. Accordingly, generalists should not delay a brief intervention while attempting to calculate a score. The available evidence instead supports a structured workflow based on identifying tobacco use, advising cessation, assessing willingness, assisting with an appropriate next step, and arranging follow-up or referral ^[65]C4.

A practical threshold framework under uncertainty

Ask: Tobacco status should be established during routine clinical contact, including ED, primary-care, inpatient, mental-health, and pharmacy encounters. In a national survey of smokers who had seen a health professional during the preceding year, 87.9% reported being asked about tobacco use ^[65]C4. However, asking was more common than the subsequent components of care, indicating that identification alone is insufficient ^[65]C4. ED providers surveyed across 10 academic EDs reported their strongest adherence to the “ask” component of the 5 A’s, although the abstract does not provide complete adherence estimates for the remaining components ^[39]C4.

Advise: A clear, nonjudgmental recommendation to quit is appropriate once current use is identified, regardless of whether the patient presents for a tobacco-related complaint or is ready to quit immediately. In the national survey, 65.8% of smokers reported receiving advice to quit, a substantially lower proportion than those reporting that they were asked about tobacco use ^[65]C4. This gap supports a low threshold for advice rather than restricting counseling to patients who volunteer motivation.

Assess: Readiness should be assessed as a conversational clinical variable, not as a prerequisite for offering help. Only 42.6% of surveyed smokers reported being asked whether they wanted to quit ^[65]C4. Patients who are not ready can still receive brief motivational counseling and an invitation to seek assistance later; patients who express interest should move directly to assistance and referral planning ^[65]C4[111]D. The Ask–Advise–Refer model is specifically intended to permit brief intervention when a clinician cannot provide comprehensive cessation treatment during the encounter ^[111]D.

Assist and arrange: A positive willingness signal is the clearest practical referral threshold in the supplied evidence. Assistance may include a direct referral to a quitline or cessation service, provision of cessation resources, and explicit follow-up arrangements; the cited studies do not establish a universal numeric threshold for referral ^{[65]C4[109]D[111]D}. A pharmacy-based pilot showed that academic detailing delivered by 11 pharmacy students to 37 community pharmacies was feasible and that, among 30 responding pharmacies, 37% reported increasing the number of patients asked about smoking six months later ^[109]D. This supports embedding referral prompts and brief intervention processes in routine workflows rather than relying solely on individual clinician initiative ^[109]D.

Setting-specific reasoning

In the ED, cessation intervention should be viewed as an adjunct to acute evaluation, not as a reason to postpone urgent care. The systematic review by Pelletier and colleagues examined interventions initiated in adult or pediatric ED settings and was designed to address clinician uncertainty about the benefits of ED-based treatment ^[42]D5. The supplied abstract does not provide enough outcome detail to specify a single superior intervention or a universal ED referral cutoff; therefore, local protocols should use brief counseling and referral pathways that can be completed within the encounter ^[42]D5.

In acute and critical care, tobacco intervention may also be linked to institutional quality processes. A review described Joint Commission national core measures requiring documented tobacco-cessation interventions for patients hospitalized with pneumonia or other pulmonary-related illnesses, acute myocardial infarction, or heart failure ^[110]D. Documentation and workflow integration are therefore important when these conditions are present, although the cited source does not establish a point-based risk score ^[110]D.

Mental-health settings warrant deliberate attention because tobacco use and dependence disproportionately affect people with mental illness, while psychiatric and mental-health clinicians may be disinclined to intervene partly because of limited tobacco-related knowledge ^[108]D. Training should therefore be considered an implementation intervention. A pilot of the 60–90-minute Counsel to Quit® program trained 297 medical, mental-health, and other professionals in an Ask–Advise–Refer approach and evaluated pre- and post-training changes in knowledge, confidence, and related outcomes ^[111]D.

Bottom line

The evidence supports a low threshold to ask and advise, a readiness-focused assessment, and a low threshold to refer when the patient expresses interest or accepts assistance ^[65]C4[111]D. No supplied reference supports withholding intervention because of diagnostic uncertainty, nor does any supplied reference validate a numeric point-of-care score or universal referral cutoff ^{[42]D5[39]C4[65]C4[109]D[111]D}.

Scope and overall safety

Tobacco-cessation interventions are intended to reduce the substantial morbidity and mortality attributable to tobacco exposure; the USPSTF identifies tobacco use as a leading preventable cause of disease, disability, and death in the United States. ^[45]A1c Smoking during pregnancy is associated with miscarriage, congenital anomalies, sudden infant death syndrome, and impaired childhood lung function, so pregnancy-related counseling and cessation treatment should be considered in the context of preventing these tobacco-related complications. ^[45]A1c The supplied evidence does not identify a specific serious complication that routinely outweighs the benefits of evidence-based cessation treatment in adults or pregnant persons. ^[45]A1c

Peri-operative complications

Active tobacco smoking is associated with a substantially increased risk of postoperative complications. ^[66]A1a The peri-operative period therefore provides an opportunity to initiate cessation support before surgery, with the dual goals of increasing abstinence and reducing postoperative morbidity. ^[66]A1a A 2023 systematic review and meta-analysis included 38 randomized studies involving 7310 participants and evaluated peri-operative cessation interventions, with abstinence at the time of surgery as the primary outcome and abstinence at 12 months as a secondary outcome. ^[66]A1a The review found that peri-operative interventions improve short-term abstinence and assessed their longer-term effect at 12 months; the supplied abstract does not provide pooled effect estimates or a definitive complication-specific estimate. ^[66]A1a

A related systematic-review protocol states that earlier evidence suggested peri-operative interventions increase short-term abstinence and may reduce postoperative complications, while noting that the evidence base had expanded and required updated synthesis. ^[67]D5 Because ^[67]D5 is a protocol rather than a completed results report, it should not be used to quantify complication reduction. ^[67]D5 Patients and surgical teams should consequently avoid interpreting cessation support as a guarantee that postoperative complications will be prevented; intervention benefit is probabilistic and depends on abstinence, timing, procedure, baseline health, and other peri-operative factors. ^{[66]A1a[67]D5}

Preoperative tobacco abstinence is particularly relevant in bariatric surgery. ^[70]C4 In one retrospective study of a university-hospital weight-loss program, current tobacco users were required to quit before scheduling surgery, reflecting the recognized association between preoperative abstinence and lower postoperative complication risk. ^[70]C4 The study examined completion of the weight-loss program rather than proving that cessation interventions themselves caused fewer complications, so its findings should not be generalized to all surgical populations. ^[70]C4

Complications and special populations

People with serious mental illness (SMI) have high tobacco-related health risk: smoking is associated with a life expectancy 15–20 years shorter than that of the general population, and comorbid diabetes further increases cardiovascular and premature-mortality risk. ^[69]B3b A retrospective electronic-health-record study examined cessation-pharmacotherapy use among smokers with type 2 diabetes in an integrated health-care system and compared treatment patterns by SMI diagnosis. ^[69]B3b This study provides information about treatment delivery in a high-risk population, but its observational design does not establish that pharmacotherapy caused or prevented complications. ^[69]B3b

Mental-health consumers and clinicians have described physiological, psychological, and social challenges that may affect cessation treatment for people with mental illness. ^[95]D These challenges can contribute to undertreatment and should prompt individualized support, monitoring, and coordination with mental-health care rather than exclusion from cessation treatment. ^[95]D The cited qualitative study does not establish a specific adverse-event rate for cessation interventions. ^[95]D

Smoking disparities may persist among ethnic-minority groups, people with psychiatric diagnoses, people with a history of substance use, and weight-concerned smokers. ^[21]C4 In a cross-sectional sample of 160 English-speaking Hispanic volunteers in the El Paso–Juárez area, smoking was assessed alongside nicotine dependence, alcohol use, acculturation, depressive symptoms, weight concern, drug use, carbon monoxide, and body composition. ^[21]C4 These findings describe correlates of smoking rather than complications of cessation treatment and should not be interpreted as evidence that any demographic group is harmed by cessation interventions. ^[21]C4

Equity, access, and interpretation of outcome data

Mobile-health cessation interventions may increase reach, affordability, scalability, and efficiency, particularly for socially disadvantaged populations that have not benefited equitably from traditional interventions and public policies. ^[68]D5 However, the cited perspective describes potential rather than definitive complication outcomes; unequal access, engagement, or effectiveness may remain important implementation concerns. ^[68]D5

Population mortality studies linking diabetes and tobacco-use disorder can demonstrate substantial disease burden and disparities, but they cannot determine whether a cessation intervention prevented or caused an individual complication. ^[94] Similarly, a survey of diabetes services on Guam describes patient perceptions of preventive and clinical services, not intervention safety or cessation-related adverse outcomes. ^[112]D Overall, complication assessment should distinguish harms of continued tobacco exposure from adverse effects of treatment, and should report peri-operative, mental-health, pregnancy, and equity outcomes separately. ^{[45]A1c[66]A1a[68]D5[69]B3b[95]D}

Overall prognosis

Tobacco dependence is a chronic, relapsing condition, and prognosis is strongly influenced by whether abstinence is achieved and maintained. The available intervention literature evaluates prognosis mainly through abstinence at treatment milestones, relapse prevention, and disease outcomes rather than through a single natural-history model. In peri-operative populations, smoking is associated with a substantially increased risk of postoperative complications, making the surgical episode an important opportunity to initiate cessation and potentially improve both short- and long-term health. ^[66]A1a

The strongest synthesis specific to surgical patients is a systematic review and meta-analysis of 38 randomised studies involving 7,310 participants. Its primary endpoint was abstinence at surgery and its secondary endpoint was abstinence at 12 months, thereby distinguishing immediate peri-operative cessation from persistence over time. ^[66]A1a The review supports assessing cessation beyond the procedure itself, because short-term abstinence does not establish durable recovery. ^[66]A1a

Persistence of tobacco use and relapse risk

Continued tobacco use after a major health event is common enough to remain a clinically important prognostic concern. In cancer care, an umbrella review of 12 meta-analyses found that cessation at or around diagnosis was associated with lower mortality across several tumour types: approximately 15–29% lower mortality in lung cancer, 20% lower mortality in head and neck cancer, and 24% lower mortality in colorectal cancer; suggestive benefits were also reported for breast, bladder, and gastrointestinal cancers. ^[28]D5 These findings indicate that cessation after diagnosis may improve survival, not merely prevent future disease. ^[28]D5

Conversely, a 2025 systematic review and meta-analysis specifically examining India found continued smoking or tobacco use after cancer diagnosis to be a substantial public-health problem, although the supplied abstract does not report the pooled prevalence estimate. ^[17]B2a Prognosis should therefore include reassessment of tobacco use after diagnosis and during treatment, rather than assuming that cancer diagnosis produces sustained abstinence. ^[17]B2a

Effectiveness across clinical and social contexts

Intervention benefits are not confined to one delivery model or population. A meta-analysis of brief behavioural interventions suitable for integrated primary care evaluated cessation outcomes using random-effects methods, supporting brief treatment as a relevant component of routine care. ^[98] A hospital-based trial of 1,357 daily smokers tested sustained post-discharge support against standard care after in-hospital counselling, reflecting the principle that intervention must continue after discharge to influence longer-term abstinence. ^[63]A1b Proactive outreach directed at smokers with low socioeconomic status was likewise evaluated in a randomised trial designed to address socioeconomic disparities in tobacco treatment and mortality. ^[47]A1b

Community and technology-enabled approaches may extend reach. In the BABEX cluster-randomised trial, 1,213 adult tobacco users in low-income communities in Delhi received either brief health-worker outreach or control treatment. ^[71]A1b A primary-care randomised trial evaluated the Dejal@bot conversational chatbot against usual clinical practice, while a systematic review and meta-analysis of conversational artificial intelligence included randomised trials reporting sustained abstinence for at least 6 months. ^[53]A1b[91] Among veterans experiencing homelessness, a comparative-effectiveness trial tested mobile contingency management, telehealth counselling, optional pharmacotherapy, standard care, and a longer-term financial incentive assessed at 3 months, addressing the need for biochemically verified longer-term outcomes in a highly vulnerable population. ^[84]

High-risk and underserved populations

People living with HIV have a particularly important long-term prognosis because smoking prevalence is reported to be two to three times higher than in the general population and is associated with increased tobacco-related morbidity and mortality. ^[9]A1b A pragmatic three-arm randomised trial in HIV clinics in Hanoi was designed to compare behavioural cessation treatment with and without pharmacotherapy, but the supplied abstract does not provide outcome results. ^[9]A1b In South Africa, a randomised trial of 280 people with HIV compared intensive behavioural counselling alone with counselling plus combination nicotine replacement therapy; abstinence at 6 months was validated using exhaled carbon monoxide and urine cotinine. ^[26]A1b

People with schizophrenia and related psychotic disorders smoke more and have approximately 10–25 years lower life expectancy, with twice the mortality rate reported in the cited study. ^[10]A1b A randomised study of 170 participants compared a personalised cessation package with brief advice and followed outcomes to 6 months, illustrating the need for active, tailored treatment in this group. ^[10]A1b Depressive symptoms may also complicate cessation; a systematic review of contingency-management interventions in smokers with depressive symptomatology assessed abstinence, mood symptoms, adherence, and tobacco-related outcomes, but only 6 studies met inclusion criteria, limiting certainty about long-term prognosis. ^[88]

Implementation and prognostic uncertainty

Evidence from Arab populations was systematically reviewed because intervention effectiveness may differ from that observed in predominantly Western samples; included interventions comprised behavioural, pharmacological, and combined approaches, with abstinence generally self-reported and biochemically verified where available. ^[97] Implementation remains a determinant of prognosis: a Chinese randomised trial evaluated an 8-week WeChat educational programme for healthcare providers with follow-up to 34 weeks, focusing on uptake of cessation practices. ^[51]A1b Digital outreach has also been studied to improve the completeness of smoking histories in electronic records, an upstream requirement for identifying patients eligible for cessation treatment and lung-cancer screening. ^[86]

A smartphone-versus-in-person mindfulness intervention has been proposed for young cancer survivors, a group in which continued smoking and depression may adversely affect outcomes, but the cited report is a trial protocol rather than an efficacy result. ^[78] Similarly, a dental-hospital process evaluation in Pakistan examined delivery of dentist-provided smokeless-tobacco cessation support, while a systematic review identified population- and health-system barriers and facilitators affecting implementation. ^[58]C4[99] These studies show that reach, treatment continuity, verification of abstinence, and structural access all influence observed prognosis. ^{[58]C4[78][86][99]}

Clinical interpretation

Prognosis should be documented longitudinally: tobacco status at baseline, abstinence at the immediate treatment milestone, biochemical confirmation when feasible, and sustained abstinence at 6–12 months or longer. ^{[26]A1b[66]A1a[84][91]} A single successful quit attempt should not be interpreted as permanent remission, and cessation support should be renewed after hospitalisation, cancer diagnosis, surgery, or relapse. ^{[17]B2a[28]D5[63]A1b[66]A1a}

Clinical importance and screening

Tobacco use during pregnancy is associated with adverse pregnancy outcomes, including miscarriage and congenital anomalies, and with adverse offspring outcomes such as sudden infant death syndrome and impaired lung function during childhood. ^[45]A1c In the United States, 7.2% of women who gave birth in 2016 reported smoking cigarettes during pregnancy. ^[45]A1c The 2021 U.S. Preventive Services Task Force (USPSTF) therefore recommends asking all adults about tobacco use and providing cessation interventions to those who use tobacco. ^[45]A1c For pregnant persons who smoke, the USPSTF recommends augmented, pregnancy-tailored counseling; this is a Grade A recommendation. ^[45]A1c The earlier USPSTF reaffirmation likewise issued a Grade A recommendation for asking all pregnant women about tobacco use and providing augmented, pregnancy-tailored counseling. ^[60]A1c

Assessment should identify cigarette smoking and other tobacco-product use, because the evidence review included tobacco cessation interventions for adults and pregnant persons and specifically evaluated behavioral interventions, pharmacotherapy, and electronic cigarettes (e-cigarettes). ^[46]A1a The 2021 evidence report searched PubMed, PsycInfo, the Database of Abstracts of Reviews of Effects, Cochrane reviews, and the Centre for Reviews and Dissemination databases, with surveillance through September 25, 2020. ^[46]A1a

Behavioral intervention and tailoring

Pregnancy-tailored counseling is the best-supported intervention category in the cited USPSTF recommendations. ^{[45]A1c[60]A1c} Counseling should be adapted to pregnancy and should account for psychosocial circumstances, including depression or anxiety, co-occurring substance use, partner and household influences, and cultural context. ^{[45]A1c[60]A1c[73]C4[72]D5[74]C4[101]D} These factors are clinically relevant because smoking before and during pregnancy and prenatal cessation were specifically examined among women reporting depression or anxiety in the 2009–2011 Pregnancy Risk Assessment Monitoring System (PRAMS), which included 34,633 women with live births. ^[73]C4

Co-occurring substance use represents a particularly high-risk population. A systematic-review protocol noted reported tobacco-smoking prevalence of 71%–95% among pregnant women who use alcohol and/or other psychoactive substances, while also emphasizing that evidence on interventions specifically targeting this group was limited and required synthesis. ^[72]D5 Accordingly, tobacco cessation support for these patients should be integrated with care for other substance use rather than delivered as an isolated intervention. ^[72]D5

Partner and relationship factors may also be relevant to cessation. A formative cross-sectional study of 143 pregnant women in Romanian obstetric clinics examined partner support and relationship characteristics in preparation for a couple-focused pregnancy tobacco-cessation trial; higher education was reported as a significant correlate of cessation. ^[74]C4 This evidence is preliminary and does not establish that couple-based treatment or education causes cessation. ^[74]C4

Culturally appropriate communication is important for populations with elevated tobacco-use prevalence. A mixed-methods project developed and refined social-marketing messages for Alaska Native and American Indian women, addressing cigarette smoking and smokeless tobacco, including the homemade product Iqmik. ^[101]D The project used focus groups and interviews involving 60 participants in the first round and quantitative survey interviews involving 52 participants in the second round. ^[101]D These findings support culturally relevant message development but do not by themselves demonstrate cessation effectiveness. ^[101]D

Pharmacotherapy and electronic cigarettes

The 2021 USPSTF evidence report systematically reviewed pharmacotherapy and e-cigarettes for cessation among adults, including pregnant persons, while also reviewing behavioral interventions. ^[46]A1a The cited material does not provide sufficient intervention-specific results here to establish a preferred pharmacotherapy or to recommend e-cigarettes for cessation during pregnancy. ^[46]A1a Pregnancy-specific treatment decisions should therefore be individualized and should prioritize the USPSTF-supported pregnancy-tailored counseling recommendation. ^{[45]A1c[46]A1a}

E-cigarette use warrants explicit assessment because e-cigarettes were used by 4.5% of the U.S. adult population in 2019, while 14.0% currently smoked cigarettes. ^[45]A1c Among perinatal populations, a PRAMS analysis from 2015–2020 examined breastfeeding initiation and breastfeeding for more than 6 months according to exclusive cigarette use, exclusive e-cigarette use, or dual use. ^[100] Because this was a pooled cross-sectional analysis, its findings are observational and should not be interpreted as proof that any tobacco product is safe during pregnancy or breastfeeding. ^[100]

Postpartum and mental-health considerations

Smoking cessation support should continue after delivery. A PRAMS analysis of 218,128 mothers from 2015–2020 examined tobacco smoking in relation to postpartum-depression symptom severity and reported an association between tobacco use and postpartum-depression symptoms. ^[36]C4 Because the study was cross-sectional, the association does not establish directionality or causation. ^[36]C4 Women with depression or anxiety before pregnancy also constitute an important cessation subgroup, as prenatal smoking, prepregnancy smoking, and prenatal cessation were specifically evaluated in this population. ^[73]C4

Health-system and policy considerations

Evidence and implementation strategies may not transfer uniformly across settings. A qualitative case study examined how health-economics evidence could inform tobacco-use policies for pregnant women in low- and middle-income countries, where intervention evidence was described as limited and much of the available economic evidence originated in high-income countries. ^[75]D5 Programs should therefore consider local tobacco products, resources, inequities, and cultural context while retaining pregnancy-tailored cessation counseling as the core evidence-based approach. ^{[45]A1c[60]A1c[75]D5}

Practical summary

Ask about tobacco use at every relevant pregnancy and postpartum encounter, provide augmented pregnancy-tailored counseling, and address mental health, other substance use, partner support, cultural context, and continued postpartum risk. ^{[45]A1c[60]A1c[72]D5[73]C4[74]C4[101]D} Discuss pharmacotherapy or e-cigarettes only with careful consideration of the pregnancy-specific evidence base, because the cited sources do not establish a preferred medication or e-cigarette strategy for pregnant persons. ^[46]A1a

Prevention and routine identification

Tobacco use should be assessed and documented as a routine component of preventive and clinical care, including cigarette, smokeless, electronic, heated, and other nicotine-product use. Inaccurate smoking histories in the electronic medical record can limit access to lung-cancer screening and tobacco-cessation interventions; a pragmatic randomized trial therefore evaluated patient-generated smoking histories collected through portal questionnaires and SMS-based surveys among adults aged 50–80 years with a history of tobacco use. ^[86] Screening workflows should capture current use, former use, product type, frequency, quit attempts, and readiness to stop, while recognizing that disability-related functional difficulties among U.S. veterans are associated with different tobacco-use patterns, including single-product and poly-tobacco use. ^[37]C4

Health professionals should provide brief advice, assess willingness to quit, offer behavioral support and pharmacotherapy when appropriate, and arrange follow-up. A systematic review and meta-analysis of 28 randomized controlled trials involving 4,343 health-professional students and 3,122 patients found that tobacco-dependence education was evaluated for effects on student knowledge, self-efficacy, clinical cessation practice, and patient smoking cessation across multiple health-professional programs. ^[76]A1a Systems should also address implementation barriers: underbilling for eligible cessation counseling was identified as a potentially important missed opportunity in a large, eight-hospital health system. ^[103]

Clinical and perioperative opportunities

Hospitalization, cancer diagnosis, HIV care, and surgery are high-value opportunities to initiate cessation treatment and link patients with continuing support. Hospital-based counseling should not end at discharge because maintaining treatment afterward is a major challenge. ^{[25]B2b[63]A1b} In a three-site randomized trial of 1,357 daily smokers who received in-hospital counseling and wanted to quit, a sustained-care model beginning at discharge was compared with standard care and incorporated referral to a telephone quitline. ^[63]A1b Pooled data from two randomized trials involving 878 hospitalized smokers evaluated automated interactive voice-response calls after discharge; intervention dose, use, satisfaction, and the relationship between engagement and cessation were assessed over 6 months. ^[25]B2b

Perioperative programs can combine brief clinician advice, telephone counseling, and nicotine-replacement therapy. A regional vascular-surgery initiative implemented these three components across 35 hospitals and evaluated outcomes among patients undergoing vascular procedures. ^[104] Cancer services should integrate structured tobacco treatment because cessation around cancer diagnosis is associated with improved survival: an umbrella review reported mortality reductions of 15–29% in lung cancer, 20% in head and neck cancer, and 24% in colorectal cancer, with suggestive benefits in breast, bladder, and gastrointestinal cancers. ^[28]D5 Persistent tobacco use after diagnosis remains common among people with cancer in India, where a systematic review synthesized 20 observational studies of continued smoking, smokeless-tobacco use, or both. ^[17]B2a

Populations requiring tailored intervention

People living with HIV should receive cessation support within HIV care. A randomized trial in South Africa assigned 280 people with HIV who smoked to intensive behavioral counseling alone or counseling plus combination nicotine-replacement therapy consisting of nicotine patches augmented by nicotine gum; abstinence at 6 months was biochemically validated using exhaled carbon monoxide and urine cotinine. ^[26]A1b In Vietnam, investigators described systematic adaptation and implementation strategies for tobacco-dependence treatment in outpatient HIV clinics, where cessation services were previously unavailable, within a type II hybrid randomized trial evaluating three interventions and their cost-effectiveness. ^[85]

Adults with serious mental illness may benefit from combined behavioral and pharmacologic treatment. A pilot randomized trial provided 12 weeks of game-based group physical activity or sedentary games, each alongside counseling and pharmacotherapy; the study enrolled 48 participants, whose baseline consumption averaged 56.3 cigarettes per week, and examined changes in smoking and psychiatric symptoms. ^[50]A1b Veterans experiencing homelessness may require flexible, low-barrier treatment. A comparative-effectiveness trial randomized 127 veterans to four weeks of mobile contingency management, five weeks of telehealth counseling, and optional 12-week pharmacotherapy, or Veterans Affairs standard care; participants were also randomized to a $100 longer-term abstinence incentive at three-month follow-up. ^[84]

Digital, smokeless-tobacco, and novel-product cessation

Digital cessation tools can extend support beyond clinic visits. An umbrella review assessed long-term effectiveness and adherence, defined around ≥6 months, for standalone text messaging, smartphone applications, internet programs, and artificial-intelligence modalities used alone or in combination. ^[87] Digital outreach may also improve the completeness of tobacco histories needed for screening and intervention. ^[86]

Smokeless-tobacco cessation is an essential prevention priority because use is associated with oral cancer and cardiovascular harm. A systematic review identified 59 studies involving brief advice, quitlines, nicotine-replacement therapy, bupropion, varenicline, mHealth, and other approaches. ^[102] For adolescents and young adults aged 15–25 years, a systematic review evaluated randomized cessation interventions for e-cigarettes, heated tobacco, and smokeless nicotine or tobacco products, while excluding studies focused on conventional cigarette cessation or prevention of initiation. ^[106]

Evidence from South Asia is expanding: a systematic review searched through February 2025 and included 37 clinical-setting studies, including 22 randomized studies, evaluating behavioral, pharmacologic, and multicomponent interventions with random-effects meta-analysis and GRADE certainty assessment. ^[59]A1a Overall, prevention and health maintenance should use repeated assessment, tailored counseling, evidence-based medication, accurate documentation, and post-visit follow-up, while adapting delivery to cancer, HIV, mental-health, homelessness, surgical, youth, and smokeless-tobacco contexts. ^{[25]B2b[26]A1b[28]D5[50]A1b[59]A1a[63]A1b[84][102][106]}